Ultragenyx Pharmaceutical Inc.: sells PRV for $203,000,000

What happened The filing says the company entered into an asset purchase agreement (the “PRV Asset Purchase Agreement”) on Oct 8, 2026 to sell a Rare Pediatric Disease Priority Review Voucher (“PRV”) to the buyer. The filing says the PRV was awarded by the U.S. Food and Drug Administration on Sep 17, 2026 upon approval of FAYUVITM (rebisufligene etisparvovec-hopf), also known as UX111, for the treatment of pediatric patients with mucopolysaccharidosis type IIIA (MPS IIIA, Sanfilippo syndrome Type A). The buyer agreed to pay the company $203,000,000, payable in cash, upon closing.

Key details

• PRV Asset Purchase Agreement entered into on Oct 8, 2026.
• PRV awarded by the FDA on Sep 17, 2026 in connection with approval of FAYUVITM (UX111) for MPS IIIA.
• Purchase price of $203,000,000 payable in cash upon closing; buyer is not named in the filing.
• Transaction contains customary representations, warranties, covenants and indemnification subject to limitations and is subject to customary closing conditions, including expiration or termination of the Hart-Scott-Rodino waiting period; the full agreement will be filed with the company’s Form 10-K for the year ended Dec 31, 2026.

Why it may matter This report was filed under Item 1.01 (entry into a material definitive agreement), which covers the sale of the Rare Pediatric Disease priority review voucher under the PRV Asset Purchase Agreement. The filing does not show why the insider traded or why the company acted.